CureVac N.V. (FRA:5CV)
Germany
· Delayed Price · Currency is EUR | Market Cap | 991.06M |
| Revenue (ttm) | 70.74M |
| Net Income (ttm) | 128.82M |
| Shares Out | n/a |
| EPS (ttm) | 0.80 |
| PE Ratio | 7.69 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 21,997 |
| Average Volume | 21,094 |
| Open | 4.402 |
| Previous Close | 4.396 |
| Day's Range | 4.378 - 4.448 |
| 52-Week Range | 2.150 - 4.948 |
| Beta | n/a |
| RSI | 40.60 |
| Earnings Date | Nov 12, 2025 |
About CureVac
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company’s portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In ad... [Read more]
Financial Performance
Financial StatementsNews
BioNTech Secures Majority Of CureVac Shares As Exchange Offer Advances
(RTTNews) - BioNTech SE (BNTX) on Wednesday announced that 184 million shares of CureVac, which is about 81.74 percent of the total shares, were successfully submitted by the December 3 deadline.
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac's issued and outstanding shares, tendered prior to the expirati...
CureVac N.V. (CVAC) Shareholder/Analyst Call Prepared Remarks Transcript
BioNTech (BNTX) Moves Forward with CureVac Acquisition
BioNTech (BNTX) Moves Forward with CureVac Acquisition
BioNTech (BNTX) Advances with Exchange Offer for CureVac Shares
BioNTech (BNTX) Advances with Exchange Offer for CureVac Shares
BioNTech’s exchange offer for German mRNA vaccine peer CureVac set to expire Dec. 3
Understood! Please provide the article or its content so I can generate the SEO-friendly meta description.
CureVac Announces Voting Results of Extraordinary General Meeting
TÜBINGEN, DE AND BOSTON, MA / ACCESS Newswire / November 25, 2025 / CureVac N.V. (Nasdaq:CVAC)(CureVac or the Company), a pioneering multinational biotech company developing a new class of transformat...
CureVac Reveals Key Voting Outcomes from Extraordinary Shareholder Meeting
CureVac’s latest Extraordinary General Meeting delivered near-unanimous backing for BioNTech’s exchange offer and key merger decisions, reshaping the company’s future.
EQS-News: CureVac Announces Voting Results of Extraordinary General Meeting • news
Company News for Nov 25, 2025
Companies In The News Are: CVAC, CAAP, NVO, BABA.
Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 350 points on Monday. Following the market opening Monday, the Dow traded up 0.16% to 46,318.84 while the NASDAQ ros...
CureVac BV (CVAC) Reports Q3 Earnings with Strong Cash Position
CureVac BV (CVAC) Reports Q3 Earnings with Strong Cash Position
CureVac (CVAC) Reports Strong Cash Position as Strategic Measures Pay Off
CureVac (CVAC) Reports Strong Cash Position as Strategic Measures Pay Off
CureVac (CVAC) Reports Decrease in Q3 EPS
CureVac (CVAC) Reports Decrease in Q3 EPS
CureVac (CVAC) Moves Closer to BioNTech Deal for mRNA Innovations
CureVac (CVAC) Moves Closer to BioNTech Deal for mRNA Innovations
CureVac GAAP EPS of €1.21, revenue of €54.13M
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates
German Federal Cartel Office clearance obtained for the planned BioNTech - CureVac transaction announced on June 12, 2025, marking an important step toward the expected closing later this year Offer p...
EQS-News: CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates
Issuer: CureVac / Key word(s): Quarterly / Interim Statement CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates 24.11.2025 / 13:10 CE...
CureVac is Now Oversold (CVAC)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
BioNTech (BNTX) Launches Exchange Offer for CureVac Shares
BioNTech (BNTX) Launches Exchange Offer for CureVac Shares
CureVac: The Hidden Value Of The mRNA Wallet
CureVac is a pioneering biotech company focused on mRNA drugs for oncology and vaccines. In biotech, value derives from research quality, patent strength, and clinical success probability, not current...
CureVac BV reports Q2 results
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business UpdatesEntered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquir...
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acqui...
CureVac's 2025 Mid-Year Financial Surge & Key Business Insights
BioNTech's acquisition of CureVac marks a pivotal moment in mRNA innovation, uniting strengths to push the boundaries of global healthcare. Jetzt den vollständigen Artikel lesen